Neural signatures of risk-taking adaptions across health, bipolar disorder, and lithium treatment.
Scholl J. et al, (2025), Mol Psychiatry
Can liaison neurology add value to patient care within a mental health setting?
Ward JH. et al, (2025), Br J Psychiatry, 226, 47 - 48
Association between a selective 5-HT4 receptor agonist and incidence of major depressive disorder: emulated target trial.
de Cates AN. et al, (2024), Br J Psychiatry, 1 - 8
The recombinant shingles vaccine is associated with lower risk of dementia.
Taquet M. et al, (2024), Nat Med
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study
DE GIORGI R., (2024), EClinicalMedicine
Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.
Taquet M. et al, (2024), Brain Commun, 6
GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia.
Harrison PJ. and Bannerman DM., (2023), Mol Psychiatry
Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization.
Taquet M. et al, (2023), Nat Med
Neuropsychiatric disorders following SARS-CoV-2 infection.
Harrison PJ. and Taquet M., (2023), Brain, 146, 2241 - 2247
Sex and age effects on risk of non-traumatic subarachnoid hemorrhage: retrospective cohort study of 124,234 cases using electronic health records
Harrison C. et al, (2023), Journal of Stroke and Cerebrovascular Diseases
Data-driven Taxonomy for Antipsychotic Medication: A New Classification System
McCutcheon R., (2023), Biological Psychiatry
Glutamatergic dysfunction leads to a hyper-dopaminergic phenotype through deficits in short-term habituation: a mechanism for aberrant salience.
Panayi MC. et al, (2022), Mol Psychiatry
Little evidence supports gabapentinoid use in bipolar disorder or insomnia
Saul H. et al, (2022), BMJ (Clinical research ed.), 379
Incidence of Epilepsy and Seizures Over the First 6 Months After a COVID-19 Diagnosis: A Retrospective Cohort Study.
Taquet M. et al, (2022), Neurology
Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.
Taquet M. et al, (2022), Lancet Psychiatry, 9, 815 - 827
CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: Advances from functional genomics and pharmacoepidemiology.
Harrison PJ. et al, (2022), Neuropharmacology
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis.
Al-Diwani A. et al, (2022), Brain, 145, 2742 - 2754
Impact of the COVID-19 Pandemic on the Global Delivery of Mental Health Services and Telemental Health: Systematic Review.
Zangani C. et al, (2022), JMIR Ment Health, 9
New drug targets in psychiatry: Neurobiological considerations in the genomics era.
Harrison PJ. et al, (2022), Neurosci Biobehav Rev, 139